Chapter 24 – Trametinib

[1]  H. Elhalawani,et al.  Doublet BRAF/MEK inhibition versus single-agent BRAF inhibition in the management of BRAF-mutant advanced melanoma, biological rationale and meta-analysis of published data , 2016, Clinical and Translational Oncology.

[2]  I. Escandell,et al.  Effective treatment with Dabrafenib and Trametinib for a BRAF‐mutated metastatic dedifferentiated malignant spindle cell neoplasm , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[3]  K. Strebhardt,et al.  Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy , 2016, Oncogene.

[4]  D. Louis,et al.  Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. , 2016, Journal of the National Cancer Institute.

[5]  M. Clausen,et al.  Allosteric small-molecule kinase inhibitors. , 2015, Pharmacology and Therapeutics.

[6]  C. Berking,et al.  Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. , 2015, European journal of cancer.

[7]  R. Braun,et al.  A cost‐effectiveness analysis of trametinib plus dabrafenib as first‐line therapy for metastatic BRAF V600‐mutated melanoma in the Swiss setting , 2015, The British journal of dermatology.

[8]  B. Neyns,et al.  Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib. , 2015, Melanoma research.

[9]  W. Hahn,et al.  Identification of an “Exceptional Responder” Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy , 2015, Molecular Cancer Research.

[10]  M. Loh,et al.  MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia. , 2015, Blood.

[11]  V. Roulstone,et al.  Trametinib radiosensitises RAS- and BRAF-mutated melanoma by perturbing cell cycle and inducing senescence. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[12]  J. Larkin,et al.  Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma , 2015, Molecular Cancer Therapeutics.

[13]  A. Hauschild,et al.  Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. , 2015, The Lancet. Oncology.

[14]  R. Roskoski.  A historical overview of protein kinases and their targeted small molecule inhibitors. , 2015, Pharmacological research.

[15]  C. Atreya,et al.  Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  L. Garraway,et al.  Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors , 2015, Molecular Cancer Therapeutics.

[17]  I. Yeh,et al.  Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion , 2015, Pigment cell & melanoma research.

[18]  A. Daud,et al.  Future of combination therapy with dabrafenib and trametinib in metastatic melanoma , 2015, Expert opinion on pharmacotherapy.

[19]  Toshio Shimizu,et al.  A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors , 2015, Investigational New Drugs.

[20]  J. Utikal,et al.  Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial , 2015, The Lancet.

[21]  B. Barlogie,et al.  Inhibiting MEK in MAPK pathway-activated myeloma , 2015, Leukemia.

[22]  F. Marincola,et al.  What’s new in melanoma? Combination! , 2015, Journal of Translational Medicine.

[23]  A. Aplin,et al.  Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma. , 2015, Cancer research.

[24]  Axel Hoos,et al.  Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab , 2015, Pigment cell & melanoma research.

[25]  X. Chen,et al.  ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma , 2015, Oncotarget.

[26]  Piotr Niezgoda,et al.  Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy , 2015, BioMed research international.

[27]  P. Queirolo,et al.  Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma. , 2015, Cancer treatment reviews.

[28]  V. Prasad,et al.  Multiplying therapies and reducing toxicity in metastatic melanoma , 2015, Cancer biology & therapy.

[29]  Jiayuh Lin,et al.  Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells , 2015, Oncotarget.

[30]  D. Planchard,et al.  A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  D. Schadendorf,et al.  Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. , 2015, European journal of cancer.

[32]  J. Malvehy,et al.  Multiple BRAF Wild-Type Melanomas During Dabrafenib Treatment for Metastatic BRAF-Mutant Melanoma. , 2015, JAMA dermatology.

[33]  K. Dwan,et al.  Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective , 2015, PharmacoEconomics.

[34]  Yong Li,et al.  Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter , 2015, Oncotarget.

[35]  M. Kelley,et al.  Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma. , 2015, Journal of the American College of Surgeons.

[36]  S. Rorive,et al.  Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma. , 2015, Melanoma research.

[37]  L. Soroceanu,et al.  The Role of BPTF in Melanoma Progression and in Response to BRAF-Targeted Therapy , 2015, Journal of the National Cancer Institute.

[38]  B. Falini,et al.  BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity. , 2015, Blood.

[39]  J. Larkin,et al.  PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel. , 2015, European journal of cancer.

[40]  J. Cebon,et al.  Response to MAPK pathway inhibitors in BRAF V600M‐mutated metastatic melanoma , 2015, Journal of clinical pharmacy and therapeutics.

[41]  P. LoRusso,et al.  Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways. , 2015, Journal of the American Academy of Dermatology.

[42]  K. Flaherty,et al.  Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  S. Welsh,et al.  Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma , 2015, Therapeutic advances in medical oncology.

[44]  C. Chung,et al.  Trametinib: a novel signal transduction inhibitor for the treatment of metastatic cutaneous melanoma. , 2015, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[45]  L. Tsvetkov,et al.  The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4 , 2015, Clinical Cancer Research.

[46]  R. Kefford,et al.  Cutaneous adverse events in patients treated with BRAF inhibitor‐based therapies for metastatic melanoma for longer than 52 weeks , 2015, The British journal of dermatology.

[47]  M. Brown,et al.  BRAF and MEK Inhibition Variably Affect GD2-specific Chimeric Antigen Receptor (CAR) T-Cell Function In Vitro , 2015, Journal of immunotherapy.

[48]  E. Van Cutsem,et al.  A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors , 2014, Clinical Cancer Research.

[49]  S. Knapp,et al.  Abstract IA09: Copper is required for oncogenic BRAF signaling and tumorigenesis , 2014 .

[50]  N. Umeweni,et al.  NICE guidance on dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma. , 2014, The Lancet. Oncology.

[51]  K. Flaherty,et al.  Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  J. Utikal,et al.  Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. , 2014, The New England journal of medicine.

[53]  C. Blank,et al.  Dabrafenib for the treatment of BRAF V600-positive melanoma: a safety evaluation , 2014, Expert opinion on drug safety.

[54]  C. Rossi,et al.  Neoadjuvant treatment with dabrafenib of unresectable localizations from occult melanoma. , 2014, Melanoma research.

[55]  J. Sarkaria,et al.  Factors Influencing the CNS Distribution of a Novel MEK-1/2 Inhibitor: Implications for Combination Therapy for Melanoma Brain Metastases , 2014, Drug Metabolism and Disposition.

[56]  Joon-Oh Park,et al.  A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. , 2014, European journal of cancer.

[57]  A. Behren,et al.  The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations , 2014, Oncoimmunology.

[58]  J. Parsons,et al.  Co-Treatment with Panitumumab and Trastuzumab Augments Response to the MEK Inhibitor Trametinib in a Patient-Derived Xenograft Model of Pancreatic Cancer1 , 2014, Neoplasia.

[59]  Ming-Chih Crouthamel,et al.  Discovery of Novel AKT Inhibitors with Enhanced Anti-Tumor Effects in Combination with the MEK Inhibitor , 2014, PloS one.

[60]  P. Ott,et al.  New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy , 2014, Drug, healthcare and patient safety.

[61]  P. Haney,et al.  Population pharmacokinetics of dabrafenib, a BRAF inhibitor: Effect of dose, time, covariates, and relationship with its metabolites , 2014, Journal of clinical pharmacology.

[62]  G. Verhoef,et al.  Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib , 2014, Annals of Hematology.

[63]  Steven P. Angus,et al.  Molecular Pathways: Adaptive Kinome Reprogramming in Response to Targeted Inhibition of the BRAF–MEK–ERK Pathway in Cancer , 2014, Clinical Cancer Research.

[64]  D. Schadendorf,et al.  Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[65]  G. Pupo,et al.  BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact , 2014, Clinical Cancer Research.

[66]  L. Haydu,et al.  Inter- and Intra-Patient Heterogeneity of Response and Progression to Targeted Therapy in Metastatic Melanoma , 2014, PloS one.

[67]  L. Kwong,et al.  Targeted therapy for melanoma: rational combinatorial approaches , 2014, Oncogene.

[68]  D. Stuart,et al.  Molecular Pathways Molecular Pathways : Response and Resistance to BRAF and MEK Inhibitors in BRAFV 600 E Tumors , 2014 .

[69]  V. de Giorgi,et al.  Cutaneous toxicities of BRAF inhibitors: clinical and pathological challenges and call to action. , 2013, Critical reviews in oncology/hematology.

[70]  A. Tolcher,et al.  Evaluation of the Effects of Food on the Single‐Dose Pharmacokinetics of Trametinib, a First‐in‐Class MEK Inhibitor, in Patients with Cancer , 2013, Journal of clinical pharmacology.

[71]  R. Dummer,et al.  Targeted therapy in melanoma – the role of BRAF, RAS and KIT mutations , 2013, EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.].

[72]  P. L. McCormack,et al.  Trametinib: First Global Approval , 2013, Drugs.

[73]  K. Nathanson,et al.  Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436) , 2013, Clinical Cancer Research.

[74]  A. King,et al.  Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions , 2013, PloS one.

[75]  Suzanne F. Jones,et al.  A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours. , 2013, European journal of cancer.

[76]  Delong Liu,et al.  MEK and the inhibitors: from bench to bedside , 2013, Journal of Hematology & Oncology.

[77]  L. Heinzerling,et al.  Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice , 2013, British Journal of Cancer.

[78]  R. Sullivan,et al.  Resistance to BRAF-targeted therapy in melanoma. , 2013, European journal of cancer.

[79]  J. Tabernero,et al.  Development of PI3K inhibitors: lessons learned from early clinical trials , 2013, Nature Reviews Clinical Oncology.

[80]  John T Parsons,et al.  Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib. , 2013, Neoplasia.

[81]  A. Kimball,et al.  Cutaneous effects of BRAF inhibitor therapy: a case series. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[82]  J. Sosman,et al.  Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  G. Madonna,et al.  Effect of dabrafenib on melanoma cell lines harbouring the BRAFV600D/R mutations , 2013, BMC Cancer.

[84]  J. Dowell,et al.  Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies. , 2012, Drugs.

[85]  S. Chandarlapaty,et al.  Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. , 2012, Cancer cell.

[86]  R. Scolyer,et al.  Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma , 2012, The British journal of dermatology.

[87]  A. Hauschild,et al.  Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. , 2012, The Lancet. Oncology.

[88]  K. Flaherty,et al.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.

[89]  K. Flaherty,et al.  Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.

[90]  K. Flaherty,et al.  Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.

[91]  A. Sivachenko,et al.  A Landscape of Driver Mutations in Melanoma , 2012, Cell.

[92]  J. Utikal,et al.  Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.

[93]  Dirk Schadendorf,et al.  Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group , 2012 .

[94]  R. Dummer,et al.  Cutaneous drug eruptions associated with the use of new oncological drugs. , 2012, Chemical immunology and allergy.

[95]  D. Schadendorf,et al.  RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  A. Tolcher,et al.  The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer , 2012, Clinical Cancer Research.

[97]  K. Flaherty,et al.  RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. , 2012, The New England journal of medicine.

[98]  S. Nelson,et al.  Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance , 2012, Nature Communications.

[99]  Tom Misteli,et al.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.

[100]  S. Tripp,et al.  KIT mutations in ocular melanoma: frequency and anatomic distribution , 2011, Modern Pathology.

[101]  W. Kolch,et al.  Raf family kinases: old dogs have learned new tricks. , 2011, Genes & cancer.

[102]  Damien Kee,et al.  Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. , 2010, Cancer cell.

[103]  V. Sondak,et al.  Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy , 2010, British Journal of Cancer.

[104]  N. Munshi,et al.  Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti‐myeloma activity in vitro and in vivo , 2010, British journal of haematology.

[105]  Karen Cichowski,et al.  Drug discovery: Inhibitors that activate , 2010, Nature.

[106]  Victor G Prieto,et al.  Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma , 2009, Clinical Cancer Research.

[107]  C. Der,et al.  Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer , 2007, Oncogene.

[108]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[109]  A. Saven,et al.  Current Therapy and New Directions in the Treatment of Hairy Cell Leukemia: A Review. , 2016, JAMA oncology.

[110]  A. Tolcher,et al.  A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[111]  A. Hauschild,et al.  Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.

[112]  M. Grever,et al.  Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

[113]  A. Marghoob,et al.  Clinico‐morphological features of BRAF inhibition–induced proliferative skin lesions in cancer patients , 2015, Cancer.

[114]  Dennis C. Friedrich,et al.  MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. , 2014, Cancer discovery.

[115]  A. Tolcher,et al.  Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma , 2014, Cancer Chemotherapy and Pharmacology.

[116]  Antoni Ribas,et al.  Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. , 2014, Cancer discovery.

[117]  A. McKenna,et al.  The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. , 2014, Cancer discovery.